Vaping, E-Cigarettes & Asthma: EVALI Risk, Aerosol Toxicity, and What South Florida Patients Need to Know

Vaping was introduced to the U.S. market in the mid-2000s with a simple promise: a cleaner, safer alternative to combustible cigarettes. A decade and a half later, the evidence tells a more complicated story — particularly for the estimated one in nine Americans living with asthma.

For patients with asthma, e-cigarettes and vaping devices are not a harm-reduction tool. They are an active asthma trigger. They cause direct airway injury through multiple parallel mechanisms, impair the lungs' defense systems, and — in the case of THC cartridges — carry the risk of EVALI, a serious and sometimes fatal acute lung injury that can masquerade as, or coexist with, an asthma exacerbation.

At Advanced Asthma Clinic in Plantation, FL, Dr. Frank Hull regularly evaluates patients whose asthma has destabilized in the context of vaping. This article provides a comprehensive, evidence-based review of what vaping does to airways, how EVALI differs from an asthma attack, and what South Florida patients need to know in an era of newly legal recreational cannabis.

What Is in Vaping Aerosol? The Airway Toxicology

A vaping device works by heating a liquid (e-liquid or "vape juice") to produce an inhalable aerosol. The liquid typically contains a base carrier (propylene glycol and/or vegetable glycerin), optional nicotine, flavoring chemicals, and in THC products, a cannabis extract. The heating process is never clean — it generates a predictable suite of airway-toxic compounds.

The Epidemiology: Vaping and Asthma Risk

The association between e-cigarette use and adverse asthma outcomes is now established across multiple study designs.

A 2019 analysis by McConnell and colleagues using data from the Population Assessment of Tobacco and Health (PATH) study — a U.S. nationally representative longitudinal cohort — found that daily e-cigarette use was associated with a 1.39-fold higher odds of asthma exacerbation compared to non-users of any tobacco product, after adjusting for combustible cigarette use and other confounders. The association was present even in vapers who had never smoked combustible cigarettes, ruling out residual confounding from prior smoking as the sole explanation.

Cross-sectional data from the 2017–2018 National Health Interview Survey (NHIS) found that among U.S. adults with current asthma, 11.4% reported current e-cigarette use — a rate substantially higher than the general population. Multiple mechanisms plausibly explain this bidirectional relationship: people with respiratory disease may vape hoping to reduce tobacco harm, while vaping itself may be contributing to increased asthma incidence.

In adolescents — the demographic with the highest vaping prevalence — a 2019 study in Pediatrics found that teens who had ever used e-cigarettes were significantly more likely to be diagnosed with asthma, with evidence of dose-response. The 2023 National Youth Tobacco Survey reported 7.7% current e-cigarette use among U.S. middle and high school students. Florida Youth Tobacco Survey data have consistently shown Florida teen vaping rates at or above the national average.

What Is EVALI?

EVALI — e-cigarette or vaping product use-associated lung injury — emerged as a recognized clinical syndrome in mid-2019 when a cluster of severe, unexplained lung injuries in young people was linked to vaping product use. The CDC surveillance identified 2,807 hospitalized cases and 68 deaths in the primary U.S. outbreak (August 2019 through February 2020). EVALI cases continue to be reported at lower incidence.

Pathophysiology

The CDC and FDA investigations identified vitamin E acetate (tocopheryl acetate) — a lipid compound used as a thickening agent in black-market and some licensed THC cartridges — as the primary causal agent. When inhaled, vitamin E acetate interferes with normal surfactant function in the alveoli, causing diffuse alveolar damage and a pattern resembling lipoid pneumonia on bronchoalveolar lavage. Lipid-laden macrophages identified in BAL fluid became a diagnostic hallmark.

Not all EVALI cases involve vitamin E acetate or THC products; a smaller proportion are linked to nicotine-only products with other adulterants or flavoring chemicals. The underlying mechanism of alveolar injury may be heterogeneous.

EVALI vs. Asthma Exacerbation: Clinical Distinction

The clinical presentation of EVALI can overlap substantially with severe asthma, making rapid differentiation critical. The table below summarizes key distinguishing features:

Critically, EVALI and asthma exacerbation are not mutually exclusive. A patient with asthma who vapes can present with EVALI-triggered acute lung injury on top of an asthma flare, creating a complex clinical picture. Any asthma patient who vapes and presents with atypical features — fever, GI symptoms, CT infiltrates, or failure to respond to standard asthma therapy — warrants urgent evaluation for EVALI.

South Florida Context: Recreational Cannabis and the EVALI Landscape

Florida Amendment 3, approved by voters in November 2024, legalized adult recreational cannabis use in Florida. By early 2026, licensed recreational dispensaries had opened across Broward County, Miami-Dade, Palm Beach, and other South Florida markets. For asthma patients in this region, the practical consequence is that THC vaping products — the highest-risk category for EVALI — are now broadly accessible in retail settings.

Secondhand Vaping Aerosol and Household Asthma Risk

For household members — particularly children — living with adults who vape indoors, secondhand aerosol exposure is a meaningful asthma trigger. Unlike secondhand tobacco smoke, vaping aerosol clears from room air more quickly and lacks the persistent surface contamination ("thirdhand smoke") associated with combustible cigarettes. However, exhaled vaping aerosol in enclosed spaces still contains ultrafine particles, VOCs, nicotine, and flavoring chemicals at concentrations that can trigger airway inflammation in sensitized individuals.

A 2020 study in Thorax found that children in homes where adults vaped had significantly higher odds of wheeze, asthma, and respiratory symptoms than children in vape-free homes, though the associations were weaker than for combustible tobacco smoke. For households with asthmatic children in Plantation, Davie, Fort Lauderdale, or elsewhere in Broward County, indoor vaping should be treated as a household asthma trigger equivalent to other chemical irritants.

Florida's Clean Indoor Air Act prohibits vaping in enclosed indoor workplaces and many public spaces, but does not regulate private residential use. Patients whose asthma worsens at home should discuss household vaping practices with all members of the household as part of trigger mitigation.

Comparing Inhalation Risk: Vaping, Smoking, and Non-Use

The conclusion the evidence supports is clear: for asthma patients, no inhaled nicotine or cannabis product is safe. Vaping is not a harm-reduction tool in this population. The safest outcome is complete cessation of all inhaled products.

Cessation: Evidence-Based Options for Vapers with Asthma

Vaping cessation faces a clinical challenge that traditional smoking cessation programs were not designed for: the majority of vapers are either young people who never smoked combustible cigarettes (and thus lack motivation framed around cancer/heart disease risk) or former smokers who switched to vaping believing it was safe. Both groups often underestimate dependence severity and airway harm.

Pharmacological Support

Nicotine replacement therapy (NRT) — patches, gum, lozenges — remains first-line for nicotine-dependent vapers seeking cessation and does not carry airway risk. Nicotine patches avoid airway exposure entirely and are particularly suitable for asthma patients. Varenicline (Chantix/generic), an alpha4beta2 nicotinic acetylcholine receptor partial agonist, is the most effective single pharmacotherapy for nicotine cessation and is appropriate for adults with asthma. Discuss options with your physician — cessation pharmacotherapy may be covered by your insurance under the Affordable Care Act preventive care mandate.

Behavioral Support

The Florida Quitline (1-877-U-CAN-NOW / 1-877-822-6669) provides free telephone counseling and NRT for Florida residents at no cost. The CDC's SmokefreeTXT program provides text-based cessation coaching for teens and young adults.

For THC-Vaping Cessation

Cannabis use disorder treatment — including cognitive-behavioral therapy and contingency management — is available through licensed addiction medicine providers. Non-inhaled cannabis delivery methods (edibles, sublingual tinctures, capsules) eliminate pulmonary exposure for patients who continue to use cannabis medically; consult your physician about appropriate non-inhaled alternatives.

When Vaping-Related Asthma Requires Advanced Medical Management

For patients whose asthma remains poorly controlled after cessation and trigger mitigation, advanced phenotyping and biologic therapy may be warranted. Vaping-induced airway inflammation can shift a patient's asthma phenotype — increasing eosinophilic or neutrophilic inflammation — and alter their response to standard inhaled corticosteroid therapy. Biologic agents targeting specific inflammatory pathways can provide transformative control in these cases.

Biologic selection is guided by blood eosinophil count, total serum IgE, FeNO (fractional exhaled nitric oxide), allergen sensitization panel, and clinical history. Our clinic offers in-house lung function testing including spirometry, bronchodilator response, and FeNO measurement. Learn more about biologic therapy for severe asthma at our Plantation clinic.